Find any stock by ticker or company name
Все права защищены.
0.78
0.00 (0.00%)
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing Cresco's leadership position in the second-largest medical marijuana market, wh.
The cannabis industry is once again going through another transitional period. With new laws set to take effect in the US in mid-December, things could ramp up for marijuana stocks. The reason for this could be the rescheduling officially coming into effect. With this, it will benefit many large MSOs and various players in the space. As well as those with the financial backing to enter the sector with some type of strategic partnership.
What will help marijuana stock investors trade more, even in the midst of laws changing in the USA? It is no secret that nothing has moved pot stocks more than news of global reform or regulatory matters. For the US, what happens at the federal level has moved the needle the most, with the recent passing of legislation to reclassify cannabis to Schedule 3.
Cresco Labs Inc. (CRLBF) Q2 2026 Earnings Call Transcript
Cresco Labs Inc. (CRLBF) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.05 per share a year ago.
CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA.
There is no data to display
